Akero Therapeutics, Inc.
AKRO
Classifica tra le azioni
#3717
Akero Therapeutics, Inc. is a biopharmaceutical firm dedicated to addressing... Akero Therapeutics, Inc. is a biopharmaceutical firm dedicated to addressing cardio-metabolic disorders, with a specific focus on nonalcoholic steatohepatitis (NASH). Its primary objective is the creation of therapeutic agents aimed at re-establishing metabolic equilibrium and enhancing overall well-being. The company's flagship investigational drug is efruxifermin (EFX), a synthetic analog of fibroblast growth factor 21. EFX is designed to shield cells from stress and modulate the systemic metabolism of fats, carbohydrates, and proteins throughout the body. This promising compound is currently undergoing evaluation in a Phase 2a clinical investigation, known as the BALANCED study, for individuals diagnosed with biopsy-confirmed NASH. Originally established as Pippin Pharmaceuticals, Inc., the organization rebranded as Akero Therapeutics, Inc. in May 2018. Founded in 2017, Akero Therapeutics maintains its corporate headquarters in South San Francisco, California.
Prezzo delle azioni
$54.65
Ultima sincronizzazione: 2025-12-09
Capitalizzazione di mercato
$4.50B
Variazione (1 giorno)
0.00%
Variazione (1 anno)
1.94%
Paese
US
Scambia Akero Therapeutics, Inc. (AKRO)
Categoria
Healthcare
Storico del prezzo dell'azione per Akero Therapeutics, Inc. (AKRO)
Prezzo di chiusura più alto: $54.59 il 2025-12-01
Prezzo di chiusura più basso: $18.95 il 2019-06-01
Prezzo di chiusura più basso: $18.95 il 2019-06-01
Storico del prezzo dell'azione di Akero Therapeutics, Inc. dal 2019 al 2026
Andamento annuale del prezzo dell'azione
| Anno | Performance |
|---|---|
| 2026 (TTM) | -0.66% |
| 2025 | 84.69% |
| 2024 | 39.17% |
| 2023 | -53.49% |
| 2022 | 118.99% |
| 2021 | -23.63% |
| 2020 | 26.67% |
| 2019 | 0.00% |
Prezzo dell'azione per aziende simili o concorrenti
| Azienda | Prezzo dell'azione | Variazione 1a% | Il paese |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.19 | -4.22% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
